203 related articles for article (PubMed ID: 28940446)
1. The PD-1 and PD-L1 pathway in recurrent respiratory papillomatosis.
Ahn J; Bishop JA; Roden RBS; Allen CT; Best SRA
Laryngoscope; 2018 Jan; 128(1):E27-E32. PubMed ID: 28940446
[TBL] [Abstract][Full Text] [Related]
2. Immune suppression in premalignant respiratory papillomas: enriched functional CD4+Foxp3+ regulatory T cells and PD-1/PD-L1/L2 expression.
Hatam LJ; Devoti JA; Rosenthal DW; Lam F; Abramson AL; Steinberg BM; Bonagura VR
Clin Cancer Res; 2012 Apr; 18(7):1925-35. PubMed ID: 22322668
[TBL] [Abstract][Full Text] [Related]
3. PD-L1 expression and CD8+ infiltration shows heterogeneity in juvenile recurrent respiratory papillomatosis.
Liu T; Greenberg M; Wentland C; Sepe B; Bowe S; Diercks G; Huynh T; Mino-Kenudson M; Schlegel R; Kodack D; Benes C; Engelman J; Hartnick C
Int J Pediatr Otorhinolaryngol; 2017 Apr; 95():133-138. PubMed ID: 28576522
[TBL] [Abstract][Full Text] [Related]
4. Safety and clinical activity of PD-L1 blockade in patients with aggressive recurrent respiratory papillomatosis.
Allen CT; Lee S; Norberg SM; Kovalovsky D; Ye H; Clavijo PE; Hu-Lieskovan S; Schlegel R; Schlom J; Strauss J; Gulley JL; Trepel J; Hinrichs CS
J Immunother Cancer; 2019 May; 7(1):119. PubMed ID: 31053174
[TBL] [Abstract][Full Text] [Related]
5. The Immune Microenvironment, Genome-wide Copy Number Aberrations, and Survival in Mesothelioma.
Thapa B; Salcedo A; Lin X; Walkiewicz M; Murone C; Ameratunga M; Asadi K; Deb S; Barnett SA; Knight S; Mitchell P; Watkins DN; Boutros PC; John T
J Thorac Oncol; 2017 May; 12(5):850-859. PubMed ID: 28257959
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of immune checkpoints in the tumour-stromal microenvironment of sebaceous gland carcinoma.
Singh L; Singh MK; Rizvi MA; Pushker N; Bakhshi S; Sen S; Kashyap S
Br J Ophthalmol; 2021 Jan; 105(1):48-56. PubMed ID: 32277010
[TBL] [Abstract][Full Text] [Related]
7. Expression of Programmed Cell Death Ligand 1 and Associated Lymphocyte Infiltration in Olfactory Neuroblastoma.
London NR; Rooper LM; Bishop JA; Xu H; Bernhardt LJ; Ishii M; Hann CL; Taube JM; Izumchenko E; Gaykalova DA; Gallia GL
World Neurosurg; 2020 Mar; 135():e187-e193. PubMed ID: 31785431
[TBL] [Abstract][Full Text] [Related]
8. PD-1/PD-L1 expression in a series of intracranial germinoma and its association with Foxp3+ and CD8+ infiltrating lymphocytes.
Liu B; Arakawa Y; Yokogawa R; Tokunaga S; Terada Y; Murata D; Matsui Y; Fujimoto KI; Fukui N; Tanji M; Mineharu Y; Minamiguchi S; Miyamoto S
PLoS One; 2018; 13(4):e0194594. PubMed ID: 29617441
[TBL] [Abstract][Full Text] [Related]
9. Association of tumour and stroma PD-1, PD-L1, CD3, CD4 and CD8 expression with DCB and OS to nivolumab treatment in NSCLC patients pre-treated with chemotherapy.
Niemeijer AN; Sahba S; Smit EF; Lissenberg-Witte BI; de Langen AJ; Thunnissen E
Br J Cancer; 2020 Aug; 123(3):392-402. PubMed ID: 32433601
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Significance of Categorizing Gastric Carcinoma by PD-L1 Expression and Tumor Infiltrating Lymphocytes.
Noh BJ; Kim JH; Eom DW
Ann Clin Lab Sci; 2018 Nov; 48(6):695-706. PubMed ID: 30610038
[TBL] [Abstract][Full Text] [Related]
11. Immune classification for the PD-L1 expression and tumour-infiltrating lymphocytes in colorectal adenocarcinoma.
Noh BJ; Kwak JY; Eom DW
BMC Cancer; 2020 Jan; 20(1):58. PubMed ID: 31992245
[TBL] [Abstract][Full Text] [Related]
12. Dual PD-L1 and TGF-b blockade in patients with recurrent respiratory papillomatosis.
Robbins Y; Friedman J; Clavijo PE; Sievers C; Bai K; Donahue RN; Schlom J; Sinkoe A; Hinrichs CS; Allen C; Abdul Sater H; Gulley JL; Norberg S
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34462327
[TBL] [Abstract][Full Text] [Related]
13. PD-1 high expression predicts lower local disease control in stage IV M0 nasopharyngeal carcinoma.
Jiang F; Yu W; Zeng F; Cheng G; Xu J; Yang S; Shui Y; Wu D; Yu XF; Wei Q
BMC Cancer; 2019 May; 19(1):503. PubMed ID: 31138162
[TBL] [Abstract][Full Text] [Related]
14. T-regulatory cells predict clinical outcome in soft tissue sarcoma patients: a clinico-pathological study.
Smolle MA; Herbsthofer L; Granegger B; Goda M; Brcic I; Bergovec M; Scheipl S; Prietl B; Pichler M; Gerger A; Rossmann C; Riedl J; Tomberger M; López-García P; El-Heliebi A; Leithner A; Liegl-Atzwanger B; Szkandera J
Br J Cancer; 2021 Aug; 125(5):717-724. PubMed ID: 34127811
[TBL] [Abstract][Full Text] [Related]
15. Profiling of VEGF Receptors and Immune Checkpoints in Recurrent Respiratory Papillomatosis.
Lam B; Miller J; Kung YJ; Wu TC; Hung CF; Roden RBS; Best SR
Laryngoscope; 2024 Jun; 134(6):2819-2825. PubMed ID: 38193541
[TBL] [Abstract][Full Text] [Related]
16. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
17. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P
Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323
[TBL] [Abstract][Full Text] [Related]
18. The perivascular microenvironment in Epstein-Barr virus positive primary central nervous system lymphoma: The role of programmed cell death 1 and programmed cell death ligand 1.
Sugita Y; Furuta T; Ohshima K; Komaki S; Miyoshi J; Morioka M; Abe H; Nozawa T; Fujii Y; Takahashi H; Kakita A
Neuropathology; 2018 Apr; 38(2):125-134. PubMed ID: 29067721
[TBL] [Abstract][Full Text] [Related]
19. The PD-1/PD-L1 axis and human papilloma virus in patients with head and neck cancer after adjuvant chemoradiotherapy: A multicentre study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG).
Balermpas P; Rödel F; Krause M; Linge A; Lohaus F; Baumann M; Tinhofer I; Budach V; Sak A; Stuschke M; Gkika E; Grosu AL; Abdollahi A; Debus J; Stangl S; Ganswindt U; Belka C; Pigorsch S; Multhoff G; Combs SE; Welz S; Zips D; Lim SY; Rödel C; Fokas E;
Int J Cancer; 2017 Aug; 141(3):594-603. PubMed ID: 28480996
[TBL] [Abstract][Full Text] [Related]
20. anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells.
Liu S; Qin T; Liu Z; Wang J; Jia Y; Feng Y; Gao Y; Li K
Cell Death Dis; 2020 May; 11(5):309. PubMed ID: 32366856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
